PACB

1.27

12.39% 0.14

Dopo l'orario di chiusura: 1.16 -0.11 -8.66%

Pacific Biosciences Of California Inc (PACB)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché PACB Giù? Forum Previsione

Precedente Chiudi:

$1.13

Aprire:

$1.12

Volume 24 ore:

10.16M

Relative Volume:

0.95

Capitalizzazione di mercato:

$347.81M

Reddito:

$188.87M

Utile/perdita netta:

$-400.38M

Rapporto P/E:

-0.8467

EPS:

-1.5

Flusso di cassa netto:

$-260.90M

1 W Prestazione:

+0.00%

1M Prestazione:

-12.41%

6M Prestazione:

-22.56%

1 anno Prestazione:

-62.76%

Intervallo 1D:

$1.12

$1.28

Intervallo di 1 settimana:

$1.08

$1.36

Portata 52W:

$1.08

$3.70

Pacific Biosciences Of California Inc Stock (PACB) Company Profile

Nome

Pacific Biosciences Of California Inc

Settore

Healthcare (1161)

Industria

Medical Devices (160)

Telefono

650-521-8000

Indirizzo

1305 O'BRIEN DRIVE, MENLO PARK, CA

Dipendente

796

Cinguettio

@pacbio

Prossima data di guadagno

2024-11-07

Ultimi documenti SEC

PACB's Discussions on Twitter

Confronta PACB con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
PACB Pacific Biosciences Of California Inc	1.27	347.81M	188.87M	-400.38M	-260.90M	-1.50
ABT Abbott Laboratories	131.93	228.81B	41.95B	13.40B	6.35B	7.65
BSX Boston Scientific Corp	100.05	149.74B	16.75B	1.85B	2.37B	1.25
SYK Stryker Corp	377.46	142.48B	22.60B	2.99B	3.49B	7.76
MDT Medtronic Plc	88.86	113.49B	33.20B	4.26B	5.47B	3.29
EW Edwards Lifesciences Corp	72.05	42.10B	5.72B	4.17B	259.90M	6.97

Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-11-11	Downgrade	UBS	Buy → Neutral
2024-06-03	Ripresa	Jefferies	Buy
2024-04-22	Downgrade	JP Morgan	Overweight → Neutral
2024-04-18	Downgrade	Goldman	Buy → Neutral
2023-12-14	Iniziato	Guggenheim	Neutral
2023-12-14	Iniziato	Stephens	Overweight
2023-12-13	Iniziato	Wolfe Research	Peer Perform
2023-11-17	Aggiornamento	UBS	Neutral → Buy
2023-10-31	Aggiornamento	Cantor Fitzgerald	Neutral → Overweight
2023-09-28	Iniziato	Bernstein	Outperform
2023-07-05	Ripresa	JP Morgan	Overweight
2023-06-30	Iniziato	Goldman	Buy
2023-05-10	Iniziato	Barclays	Equal Weight
2023-03-31	Aggiornamento	TD Cowen	Market Perform → Outperform
2023-02-02	Iniziato	UBS	Neutral
2023-01-20	Downgrade	Cantor Fitzgerald	Overweight → Neutral
2023-01-05	Iniziato	Scotiabank	Sector Outperform
2022-01-21	Ripresa	Cantor Fitzgerald	Overweight
2022-01-06	Ripresa	Piper Sandler	Neutral
2021-10-15	Ripresa	Cowen	Market Perform
2021-09-27	Iniziato	Canaccord Genuity	Buy
2021-02-11	Aggiornamento	Piper Sandler	Neutral → Overweight
2020-11-03	Downgrade	Piper Sandler	Overweight → Neutral
2020-10-02	Aggiornamento	JP Morgan	Neutral → Overweight
2020-09-09	Iniziato	Morgan Stanley	Equal-Weight
2020-06-02	Ripresa	Cantor Fitzgerald	Overweight
2020-03-09	Ripresa	Cantor Fitzgerald	Overweight
2019-10-15	Aggiornamento	Piper Jaffray	Neutral → Overweight
2019-04-02	Downgrade	Stephens	Overweight → Equal-Weight
2018-10-19	Iniziato	Cowen	Outperform
2017-11-03	Downgrade	First Analysis Sec	Overweight → Equal-Weight
2017-09-28	Downgrade	CL King	Buy → Neutral
2016-11-03	Reiterato	Cantor Fitzgerald	Buy
2016-06-27	Iniziato	CL King	Buy
2016-04-15	Iniziato	First Analysis Sec	Overweight
2016-02-04	Downgrade	Piper Jaffray	Overweight → Neutral
2016-01-04	Reiterato	Cantor Fitzgerald	Buy
2015-10-23	Aggiornamento	Piper Jaffray	Neutral → Overweight
2015-08-27	Iniziato	Cantor Fitzgerald	Buy
2015-02-04	Reiterato	Maxim Group	Buy
2013-09-26	Reiterato	Maxim Group	Buy
2013-01-14	Reiterato	Maxim Group	Buy

Mostra tutto

Pacific Biosciences Of California Inc Borsa (PACB) Ultime notizie

Mar 28, 2025

Pacific Biosciences of California appoints CFO - MSN

Mar 28, 2025

Mar 27, 2025

PacBio names Jim Gibson as new CFO By Investing.com - Investing.com South Africa

Mar 27, 2025

Tech Giant CFO Who Raised $1B+ Joins PacBio: Ex-Tesla, Apple Executive to Drive Growth - Stock Titan

Mar 27, 2025

Publications March 2025 - Pacific Biosciences

Mar 27, 2025

Mar 25, 2025

Assessing Pacific Biosciences: Insights From 6 Financial Analysts - Benzinga

Mar 25, 2025

Mar 24, 2025

ATTENTION PACB SHAREHOLDERS: Investors Who Lost Money on Pacific Biosciences of California, Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation - ACCESS Newswire

Mar 24, 2025

Mar 23, 2025

Here's Why You Should Retain PacBio Stock in Your Portfolio Now - MSN

Mar 23, 2025

Mar 22, 2025

Cathie Wood's Ark Invest Scoops Up Iridium, Beam, Pacific Biosciences While Offloading Illumina And Amgen - Benzinga

Mar 22, 2025

Mar 21, 2025

Pacific Biosciences of California (PACB) Advances While Market Declines: Some Information for Investors - MSN

Mar 21, 2025

Here's Why You Should Retain PacBio Stock in Your Portfolio for Now - MSN

Mar 21, 2025

Mar 19, 2025

PacBio, Take2 Resolve DNA Sequencing Patent Infringement Dispute - Bloomberg Law

Mar 19, 2025

Mar 18, 2025

Is Pacific Biosciences of California, Inc. (PACB) the Most Volatile Stock Under $3 For Day Trading? - Insider Monkey

Mar 18, 2025

10 Most Volatile Stocks Under $3 For Day Trading - Insider Monkey

Mar 18, 2025

Inspiring the next generation of scientists: How multidisciplinary science powers PacBio technology - Pacific Biosciences

Mar 18, 2025

Mar 17, 2025

Q4 Rundown: PacBio (NASDAQ:PACB) Vs Other Life Sciences Tools & Services Stocks - The Globe and Mail

Mar 17, 2025

Mar 14, 2025

Pacific Biosciences of California (PACB) Increases Yet Falls Behind Market: What Investors Need to Know - Yahoo Finance

Mar 14, 2025

ATTENTION PACB SHAREHOLDERS: Investors who lost money on Pacific Biosciences of California, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation - ACCESS Newswire

Mar 14, 2025

Pacific Biosciences secures extended lease with rent abatement By Investing.com - Investing.com Australia

Mar 14, 2025

Mar 13, 2025